<DOC>
	<DOCNO>NCT02194894</DOCNO>
	<brief_summary>In first pilot study , examine effect acetaminophen dose adult patient NAFLD comparison effect healthy control group . Both group receive 3 gram ( g ) acetaminophen , maximum recommend daily dose , daily 14 day . We hypothesize NAFLD patient prone APAP toxicity normal controls.Treatment stop two week follow condition : Treatment APAP stop healthy volunteer ALT and/or AST reach three time ULN . In patient NAFLD , treatment stop : ALT AST reach ≥ three time upper limit entry value ≥ 5 time ULN ; ALT AST &gt; 3 time ULN TBili &gt; 2xULN INR &gt; 1.5 ; ALT AST &gt; 3 time ULN appearance fatigue , nausea , vomit , right upper quadrant pain tenderness , fever , rash , and/or eosinophilia ( &gt; 5 % ) . We follow conservative approach derive FDA guideline stop medication expect cause drug induce liver injury ( DILI ) . Indeed , FDA allow continuation medication ALT AST &gt; 8x ULN absence elevate Tbili INR . Patients hepatotoxicity close monitoring liver enzymes normalize . Taking acetaminophen 3g daily show safe acceptable . We follow strict criterion monitor stopping rule however usually case toxicity patient admit monitoring .</brief_summary>
	<brief_title>The Effect Acetaminophen Non-alcoholic Fatty Liver Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>NAFLD patient : Inclusion criterion : 1 . `` Presence NAFLD '' : This define presence least two follow criterion : ( ) suggestion liver fat imaging study ( ultrasound , CT scan , MRI MR spectroscopy ) perform 6 month prior enrollment ; ( b ) elevate aminotransferase level ( ALT &gt; 31 U/L men &gt; 19 U/L woman , AST &gt; 30 U/L ) least two occasion 6 month precede enrollment ; ( c ) presence metabolic syndrome , define accord modify AHA/NCEP criterion . Biopsies require ; however , previous biopsy do within 6 month prior initiation study consider diagnostic typical finding NAFLD describe cause liver disease rule ; 2 . Individuals 1870 year old ; 3 . Written informed consent . Exclusion criterion : 1 . Serum ALT &gt; 3 time ULN baseline . 2 . Evidence another form liver disease include viral hepatitis , autoimmune hepatitis , cholestatic liver disease , Wilson 's disease , Alpha1antitrypsin deficiency , hemochromatosis DILI . 3 . History excess alcohol ingestion , average 30 gm/day ( 3 drink per day ) previous 10 year , history alcohol intake average great 10 gm/day ( 1 drink per day : 7 drink per week ) previous one year . 4 . Evidence liver cirrhosis lab image . 5 . History gastrointestinal bypass surgery ingestion drug know produce hepatic steatosis previous 6 month . 6 . Significant systemic major illness liver disease . 7 . Positive test antiHIV . 8 . Active substance abuse . 9 . Pregnancy inability practice adequate contraception woman childbearing potential 10 . Evidence hepatocellular carcinoma . 11 . Any condition , opinion investigator , would impede competence compliance . 12 . Serum creatinine &gt; 1.5 mg/dl . 13 . Starting medication show cause drug induce liver injury ( eg , augmentin , statin . ) within one month prior enrollment . Medications know cause DILI take one month prior enrollment ( statin ) exclusion . Healthy Controls : Inclusion criterion : 1 . Individuals 1870 year old 2 . Normal Liver enzymes 3 . Negative hepatitis B surface antigen , hepatitis C antibody 4 . BMI ( 18.5 24.9 ) kg/m2 5 . Written informed consent . Exclusion criterion : 1 . Presence metabolic syndrome , define accord modify AHA/NCEP criterion 2 . Taking concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Acetaminophen , Non-alcoholic Fatty Liver Disease ( NAFLD )</keyword>
</DOC>